Literature DB >> 27447923

Functional impairment of CMV-reactive cellular immunity during pregnancy.

Edith Reuschel1, Sascha Barabas2, Florian Zeman3, Hanna Bendfeldt2, Anne Rascle2, Ludwig Deml2, Birgit Seelbach-Goebel1.   

Abstract

Cytomegalovirus (CMV) is the most common congenital viral infection. Mother-to-child transmission can cause severe child disability. Intact CMV-specific cell-mediated immunity (CMI) was shown to prevent uncontrolled replication in healthy individuals. This study aimed to determine whether CMV-specific CMI is impaired in pregnant women, thus potentially increasing the overall risk for active CMV replication and transmission. CMV-specific CMI in peripheral blood of 60 pregnant women was determined using T-Track® CMV for detection of IE-1 and pp65-reactive effector cells by IFN-γ ELISpot, and compared to the CMV-IgG and -IgM serostatus. CMV-specific CMI was detected in 65% of CMV-seropositive pregnant women. Five percent of CMV-IgG seronegative women showed IE-1- but not pp65-reactive cells. The overall number of CMV-reactive cells in pregnant women was significantly lower compared to a matched non-pregnant control group (P < 0.001). No significant difference in CMV-specific CMI was detected in the course of the three trimesters of pregnancy of CMV-IgG seropositive women. Postpartum (median days postnatal = 123), IE-1- and pp65-specific CMI remained significantly lower than in the non-pregnant control group (P < 0.001 and 0.0032, respectively). Functional analysis of CMV-reactive immune cells using T-Track® CMV therefore suggests a systemic down-regulation of CMV-specific CMI in pregnant women. Further studies are needed to investigate whether this may be indicative of a higher susceptibility to CMV reactivation or transmission. J. Med. Virol. 89:324-331, 2017.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  cell-mediated immunity; cytomegalovirus; interferon (IFN)-γ-enzyme-assay ELISpot; pregnancy

Mesh:

Substances:

Year:  2016        PMID: 27447923     DOI: 10.1002/jmv.24639

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  7 in total

1.  Cytomegalovirus shedding from breastmilk and mucosal sites in healthy postpartum women: A pilot study.

Authors:  Tali Azenkot; Benjamin Zaniello; Margaret L Green; Stacy Selke; Meei-Li Huang; Amalia Magaret; Anna Wald; Christine Johnston
Journal:  J Med Virol       Date:  2019-01-03       Impact factor: 2.327

2.  Modulation of the Host Environment by Human Cytomegalovirus with Viral Interleukin 10 in Peripheral Blood.

Authors:  Vivian P Young; Margarette C Mariano; Carolyn C Tu; Kathryn M Allaire; Selmir Avdic; Barry Slobedman; Juliet V Spencer
Journal:  J Infect Dis       Date:  2017-03-15       Impact factor: 5.226

Review 3.  The dilemma of cytomegalovirus and hepatitis B virus interaction.

Authors:  Muzammil M Khan; Mukarram J Ali; Hira Hanif; Muhammad H Maqsood; Imama Ahmad; Javier E G Alvarez; Maria-Andreea Catana; Daryl T Y Lau
Journal:  Gastroenterol Rep (Oxf)       Date:  2022-05-26

4.  Validation of T-Track® CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients.

Authors:  Bernhard Banas; Carsten A Böger; Gerhard Lückhoff; Bernd Krüger; Sascha Barabas; Julia Batzilla; Mathias Schemmerer; Josef Köstler; Hanna Bendfeldt; Anne Rascle; Ralf Wagner; Ludwig Deml; Joachim Leicht; Bernhard K Krämer
Journal:  BMC Immunol       Date:  2017-03-07       Impact factor: 3.615

5.  An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity.

Authors:  Sascha Barabas; Theresa Spindler; Richard Kiener; Charlotte Tonar; Tamara Lugner; Julia Batzilla; Hanna Bendfeldt; Anne Rascle; Benedikt Asbach; Ralf Wagner; Ludwig Deml
Journal:  BMC Immunol       Date:  2017-03-07       Impact factor: 3.615

6.  Evaluation of T-activated proteins as recall antigens to monitor Epstein-Barr virus and human cytomegalovirus-specific T cells in a clinical trial setting.

Authors:  Nina Körber; Uta Behrends; Ulrike Protzer; Tanja Bauer
Journal:  J Transl Med       Date:  2020-06-17       Impact factor: 5.531

7.  Roles of GP33, a guinea pig cytomegalovirus-encoded G protein-coupled receptor homolog, in cellular signaling, viral growth and inflammation in vitro and in vivo.

Authors:  Miei Takeda; Shinji Watanabe; Harutaka Katano; Kazuma Noguchi; Yuko Sato; Sayaka Kojima; Takuya Miura; Ryuichi Majima; Souichi Yamada; Naoki Inoue
Journal:  PLoS Pathog       Date:  2018-12-20       Impact factor: 6.823

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.